RESUMEN
1. Chronic treatment of Sprague-Dawley rats with the new terpenoid mucoregulating drug (I) did not modify activities of the drug-metabolizing enzymes (phase I and phase II) of liver and lung. 2. Acute treatment of rats with I did not affect the GSH content of liver and lung, but administration of the corresponding alpha, beta-unsaturated ketone (II) produced considerable GSH depletion in both tissues, the original GSH levels being restored after a few hours. 3. The results are discussed in comparison with those previously obtained with the structurally related drug trans-sobrerol (III).
Asunto(s)
Ciclohexanoles/farmacología , Glutatión/metabolismo , Hígado/enzimología , Pulmón/enzimología , Preparaciones Farmacéuticas/metabolismo , Animales , Ciclohexenos , Sistema Enzimático del Citocromo P-450/metabolismo , Cetonas/farmacología , Hígado/efectos de los fármacos , Hígado/metabolismo , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Masculino , Oxidorreductasas/metabolismo , Ratas , Ratas Endogámicas , Terpenos/farmacologíaRESUMEN
1. Metabolism of 14C-trans-sobrerol (I) by Sprague-Dawley rat liver microsomes did not result in covalent binding to proteins, lipid peroxidation or cytochrome P-450 destruction. 2. Subacute and chronic treatment of Sprague-Dawley rats with (I) resulted only in an increase in liver cytosolic GSH-S-transferase. 3. Acute treatment of rats with trans-sobrerol or its metabolite, 8-hydroxycarvotanacetone (II) produced considerable GSH depletion, faster in the case of II, in both liver and lung; the original GSH levels were restored within 24 h. No significant increase in lipid peroxidation was found even when GSH was at its lowest level. 4. UDP-glucuronyltransferase and GSH-S-transferase conjugation occurred with trans-sobrerol and some of its metabolites although at low rates.